A Prospective Follow-Up of Adipocytokines in Cohort @entity1 With Gout: Association With XXXX But Not With Clinical Inflammatory Findings: Strobe-Compliant Article.

@entity1 @entity2298 @entity414 @entity101 @entity28 @entity1243 @entity1674 @entity1254 @entity158 @entity209 @entity210 @entity165 @entity1851
UNASSIGNED: The aim of this study was to determine the levels of @entity1243 ( @entity1243 ) and @entity1254 ( @entity1254 ) in @entity1 with @entity210 and its relationship with joint inflammatory data and/or with @entity209 ( @entity209 ) variables, during 1 year follow-up.Forty-one @entity1 (40 males) with @entity210 diagnosis, attending for the first time to a rheumatology department, were included. Evaluations were performed baseline, at 6 and 12 months. Variables included the following: demographic, clinical and laboratory data related to @entity210 and associated diseases. @entity1243 and @entity1254 determinations by the ELISA method were performed in frozen serum from each visit. The pharmacological and no-pharmacological treatment for @entity210 and associated diseases was individualized for each @entity1 according to published guidelines. Statistical analysis included Mann-Whitney U test, Fisher test, x, ANOVA, Cochran Q, Pearson and Spearman correlation tests, as well as linear regression.In the baseline evaluation, 29.2% had @entity209 ( @entity2298 66%, @entity101 44% and @entity28 37%); @entity1 with @entity209 had higher @entity1851 (CRP) levels [34.1  28.6 vs. 12.2  11.2mg/dL, P=0.033]. Although not significant, also had higher @entity1243 and lower @entity1254 levels (3.2  3.0 vs. 1.9  1.2ng/mL, P=0.142 and 40.5  26.8 vs. 38.0  24.9ng/mL, P=0.877, respectively). During follow-up, our @entity1 had significant improvement in serum @entity414 (sUA) levels and variables evaluating @entity158 (P  <= 0.05). @entity209 tended to persist or even worsen during the monitoring period: significant increase in total @entity165 (P=0.004), tendency to higher @entity1674 (P=0.883) and slight improvement in glycaemia (P=0.052). @entity1243 values increased significantly during follow-up (P=0.001) while @entity1254 levels diminished slightly (P=0.317). Neither @entity1243 nor @entity1254 values showed important correlation (r>0.5) with metabolic variables or joint swelling.This study suggests that in @entity1 with @entity210 , concentrations of @entity1243 and @entity1254 are more in line with the metabolic state than with clinical disease activity.
